Seyed Ehsan Enderami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seyed Ehsan Enderami has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
Reyhaneh Nassiri Mansour
19 shared publications- Fatemeh Soleimanifar
Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
15 shared publications Masoud Soleimani
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
15 shared publications- Mohammad Foad Abazari
Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
13 shared publications Ehsan Saburi
Medical Genetics and Molecular Medicine Department, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
11 shared publications- Abdolreza Ardeshirylajimi
Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
10 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in Preprints.org
Isolation and Structural Characterization of Secondary Metabolites and Immunomodulatory Activity of Polysaccharides from Trametes hirsuta (Wulfen) Lloyd
Mushroom-derived products are increasingly recognized as promising immunomodulatory therapeutics. This study aimed to evaluate the immunomodulatory properties of polysaccharides and characterize secondary metabolites from Trametes hirsuta (Wulfen) Lloyd. Sterol derivatives were isolated using column chromatography, while polysaccharides were obtained via hot water extraction, purified by ethanol precipitation, and dialyzed. Polysaccharide content was measured with the phenol-sulfuric acid method. Antioxidant activity was assessed using DPPH and FRAP assays. The volatile fraction was obtained by hydrodistillation and analyzed by GC-MS Spectrometry. The total phenolic content was determined by the Folin-Ciocalteu method. The cytotoxicity of the polysaccharide fraction on THP-1 cells was evaluated using the XTT assay in 2D and 3D cultures and its effects on IL-1β and TNF-α secretion were assessed. Identified compounds included ergosterol, ergosterol peroxide and ergosteryl acetate, and the phenolic compound 3,2,6-di-tert-butyl-4-(hydroxymethyl) benzoic acid, which was identified for the first time in T. hirsuta. The polysaccharide content was quantified at 53.10 ± 2.87%. Cytotoxicity testing showed non-toxic doses of 10 and 240 μg/mL in 2D cultures, and 10 and 670 μg/mL in 3D cultures. Using these concentrations, the extract induced a dose-dependent increase in IL-1β and TNF-α secretion. Total phenolic content of the methanol extract was 41.64 ± 3.81 mg gallic acid equivalent per gram of dry weight. The essential oil was rich in alcohols (19.64%) and aldehydes (16.43%). The methanol extract exhibited the highest antioxidant activity in FRAP assay (408.1667±0.1116 mmol Fe2+/gram dry weight). These findings support the immunomodulatory activity of T. hirsuta polysaccharides and warrant further investigation of their underlying receptor-mediated mechanisms.
- 28 August 2026
- Published by MDPI AG in Preprints.org
Open AccessIsolation and Structural Characterization of Secondary Metabolites and Immunomodulatory Activity of Polysaccharides from Trametes hirsuta (Wulfen) Lloyd
Mushroom-derived products are increasingly recognized as promising immunomodulatory therapeutics. This study aimed to evaluate the immunomodulatory properties of polysaccharides and characterize secondary metabolites from Trametes hirsuta (Wulfen) Lloyd. Sterol derivatives were isolated using column chromatography, while polysaccharides were obtained via hot water extraction, purified by ethanol precipitation, and dialyzed. Polysaccharide content was measured with the phenol-sulfuric acid method. Antioxidant activity was assessed using DPPH and FRAP assays. The volatile fraction was obtained by hydrodistillation and analyzed by GC-MS Spectrometry. The total phenolic content was determined by the Folin-Ciocalteu method. The cytotoxicity of the polysaccharide fraction on THP-1 cells was evaluated using the XTT assay in 2D and 3D cultures and its effects on IL-1β and TNF-α secretion were assessed. Identified compounds included ergosterol, ergosterol peroxide and ergosteryl acetate, and the phenolic compound 3,2,6-di-tert-butyl-4-(hydroxymethyl) benzoic acid, which was identified for the first time in T. hirsuta. The polysaccharide content was quantified at 53.10 ± 2.87%. Cytotoxicity testing showed non-toxic doses of 10 and 240 μg/mL in 2D cultures, and 10 and 670 μg/mL in 3D cultures. Using these concentrations, the extract induced a dose-dependent increase in IL-1β and TNF-α secretion. Total phenolic content of the methanol extract was 41.64 ± 3.81 mg gallic acid equivalent per gram of dry weight. The essential oil was rich in alcohols (19.64%) and aldehydes (16.43%). The methanol extract exhibited the highest antioxidant activity in FRAP assay (408.1667±0.1116 mmol Fe2+/gram dry weight). These findings support the immunomodulatory activity of T. hirsuta polysaccharides and warrant further investigation of their underlying receptor-mediated mechanisms.
- Open Access
- 28 May 2026
- Published by Elsevier in Current Therapeutic Research
- Vol. 105
Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety
- 28 May 2026
- Published by Elsevier in Current Therapeutic Research
- Vol. 105
Open AccessMonoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety
- 3 September 2025
- Published by Wiley in Plasma Processes and Polymers
- Vol. 22 (10)
Designing a Suitable Model for Evaluating the Penetration Depth of Cold Atmospheric Plasma by Implanting B16F10 Melanoma Cells on Polycaprolactone Nanofibrous Scaffolds
Cold atmospheric plasma (CAP) is increasingly recognized for its potential in melanoma cancer treatment due to its ability to induce cell death selectively in cancer cells while sparing normal L929 fibroblast cells. In this study, culturing B16‐F10 melanoma and L929 fibroblast cell lines on polycaprolactone (PCL) nanofiber scaffolds, the penetration depth of CAP effects, especially cytotoxicity and selectivity, in a three‐dimensional (3D) scaffold has been examined. Results from MTT assays, ROS measurements, and flow cytometry confirmed that CAP effectively reduces the viability of melanoma cells across scaffold layers, with a higher impact on surface layers and a gradual decline in deeper layers. ROS production followed a similar trend, demonstrating CAP penetration through multiple layers while retaining its selective cytotoxic effects. Flow cytometry analysis further supported CAP‐induced apoptosis in melanoma cells, with reduced effectiveness in deeper layers. Finally, a strong linear regression model (R2 > 0.97) enabled extrapolation of cell viability across scaffold layers, yielding an estimated effective plasma penetration depth of 116–166 µm based on the 50% viability threshold (IC50). These findings highlight the suitability of PCL‐based 3D scaffolds as in vitro models for studying CAP penetration and reinforce CAP's potential as a targeted therapy for melanoma.
- 3 September 2025
- Published by Wiley in Plasma Processes and Polymers
- Vol. 22 (10)
Designing a Suitable Model for Evaluating the Penetration Depth of Cold Atmospheric Plasma by Implanting B16F10 Melanoma Cells on Polycaprolactone Nanofibrous Scaffolds
Cold atmospheric plasma (CAP) is increasingly recognized for its potential in melanoma cancer treatment due to its ability to induce cell death selectively in cancer cells while sparing normal L929 fibroblast cells. In this study, culturing B16‐F10 melanoma and L929 fibroblast cell lines on polycaprolactone (PCL) nanofiber scaffolds, the penetration depth of CAP effects, especially cytotoxicity and selectivity, in a three‐dimensional (3D) scaffold has been examined. Results from MTT assays, ROS measurements, and flow cytometry confirmed that CAP effectively reduces the viability of melanoma cells across scaffold layers, with a higher impact on surface layers and a gradual decline in deeper layers. ROS production followed a similar trend, demonstrating CAP penetration through multiple layers while retaining its selective cytotoxic effects. Flow cytometry analysis further supported CAP‐induced apoptosis in melanoma cells, with reduced effectiveness in deeper layers. Finally, a strong linear regression model (R2 > 0.97) enabled extrapolation of cell viability across scaffold layers, yielding an estimated effective plasma penetration depth of 116–166 µm based on the 50% viability threshold (IC50). These findings highlight the suitability of PCL‐based 3D scaffolds as in vitro models for studying CAP penetration and reinforce CAP's potential as a targeted therapy for melanoma.
- Open Access
- 14 February 2025
- Published by IntechOpen
Natural Polysaccharides in Breast Cancer: Fucoidan’s Role in Enhancing Cisplatin Cytotoxicity and Reducing Chemotherapy Resistance
Cancer is one of the leading causes of death worldwide. Recent advancements in chemotherapy, particularly using natural drug-based strategies, have shown promise. This study evaluated the antitumor and anti-inflammatory effects of a combination of the brown alga Sargassum ilicifolium with cisplatin in vitro. After collecting and identifying the algae, fucoidan and alginate were extracted. The antioxidant activity was assessed using DPPH and Ferric Reducing Ability of Plasma (FRAP) assays. The cytotoxic effects on the MDA-MB-231 breast cancer cell line were evaluated in both 2D and 3D cultures using the XTT assay. Fucoidan and alginate yielded 7203 and 441 mg per 100 grams of dried algae, respectively. Total polysaccharide content in the fraction was estimated to be 89.39 mg/g dried algae weight. Fucoidan-rich extract exhibited higher antioxidant properties compared to alginate-rich extract. Also, the combination treatment significantly enhanced cytotoxicity, with the IC50 of fucoidan-rich extract reduced from 177.9 ± 8.7 to 79.3 ± 4.6 μg/ml in 2D culture when combined with cisplatin. In 3D culture, the IC50 decreased from over 800 ± 78.5 to 364.5 ± 41.7 μg/ml. Additionally, the fucoidan-rich extract significantly decreased IL-1β and IL-6 cytokine secretion in macrophages. These findings suggest combining cisplatin with fucoidan-rich extract enhances antitumor efficacy and may reduce chemotherapy side effects.
- 14 February 2025
- Published by IntechOpen
Open AccessNatural Polysaccharides in Breast Cancer: Fucoidan’s Role in Enhancing Cisplatin Cytotoxicity and Reducing Chemotherapy Resistance
Cancer is one of the leading causes of death worldwide. Recent advancements in chemotherapy, particularly using natural drug-based strategies, have shown promise. This study evaluated the antitumor and anti-inflammatory effects of a combination of the brown alga Sargassum ilicifolium with cisplatin in vitro. After collecting and identifying the algae, fucoidan and alginate were extracted. The antioxidant activity was assessed using DPPH and Ferric Reducing Ability of Plasma (FRAP) assays. The cytotoxic effects on the MDA-MB-231 breast cancer cell line were evaluated in both 2D and 3D cultures using the XTT assay. Fucoidan and alginate yielded 7203 and 441 mg per 100 grams of dried algae, respectively. Total polysaccharide content in the fraction was estimated to be 89.39 mg/g dried algae weight. Fucoidan-rich extract exhibited higher antioxidant properties compared to alginate-rich extract. Also, the combination treatment significantly enhanced cytotoxicity, with the IC50 of fucoidan-rich extract reduced from 177.9 ± 8.7 to 79.3 ± 4.6 μg/ml in 2D culture when combined with cisplatin. In 3D culture, the IC50 decreased from over 800 ± 78.5 to 364.5 ± 41.7 μg/ml. Additionally, the fucoidan-rich extract significantly decreased IL-1β and IL-6 cytokine secretion in macrophages. These findings suggest combining cisplatin with fucoidan-rich extract enhances antitumor efficacy and may reduce chemotherapy side effects.
- Open Access
- 1 February 2025
- Published by Negah Scientific Publisher in Research in Molecular Medicine
- Vol. 13 (1) , 9-22
New Insights and Perspectives on Human Menstrual Blood-derived Stem Cells as a New Cell-based Delivery Technology in Regenerative Medicine
Background: Menstrual blood has been identified as an important source for the isolation of mesenchymal stem cells (MSCs). These stem cells can easily and non-invasively be harvested from menstrual blood during menstrual shedding. There has been extensive research on the differentiation potential of menstrual blood-derived stem cells (MenSCs) and their application in regenerative medicine and the treatment of diseases. Materials and Methods: The aim of this paper was to review the current and future application of MenSCs in the field of regenerative medicine and cell therapy based on an electronic search in various databases, like Scopus, PubMed, and Google Scholar for English-language studies. The application of MenSCs in regenerative medicine can be the window of hope for the treatment of various diseases and disabilities, such as female infertility, type 1 diabetes, myocardial infarction, wound healing, neurodegenerative diseases, and many other conditions that were thought to be incurable in the past. Conclusion: Nowadays, the use of MenSC as a novel source of MSCs has garnered special interest among scientists due to two important factors: Non-invasive accessibility and the immunomodulatory potential of these cells, which have historically posed significant obstacles in the field of stem cell therapy. To date, there has been substantial research on these cells, and many studies are ongoing, as scientists seek to leverage their differentiation potential and optimize differentiation conditions and protocols for their application in regenerative medicine.
- 1 February 2025
- Published by Negah Scientific Publisher in Research in Molecular Medicine
- Vol. 13 (1) , 9-22
Open AccessNew Insights and Perspectives on Human Menstrual Blood-derived Stem Cells as a New Cell-based Delivery Technology in Regenerative Medicine
Background: Menstrual blood has been identified as an important source for the isolation of mesenchymal stem cells (MSCs). These stem cells can easily and non-invasively be harvested from menstrual blood during menstrual shedding. There has been extensive research on the differentiation potential of menstrual blood-derived stem cells (MenSCs) and their application in regenerative medicine and the treatment of diseases. Materials and Methods: The aim of this paper was to review the current and future application of MenSCs in the field of regenerative medicine and cell therapy based on an electronic search in various databases, like Scopus, PubMed, and Google Scholar for English-language studies. The application of MenSCs in regenerative medicine can be the window of hope for the treatment of various diseases and disabilities, such as female infertility, type 1 diabetes, myocardial infarction, wound healing, neurodegenerative diseases, and many other conditions that were thought to be incurable in the past. Conclusion: Nowadays, the use of MenSC as a novel source of MSCs has garnered special interest among scientists due to two important factors: Non-invasive accessibility and the immunomodulatory potential of these cells, which have historically posed significant obstacles in the field of stem cell therapy. To date, there has been substantial research on these cells, and many studies are ongoing, as scientists seek to leverage their differentiation potential and optimize differentiation conditions and protocols for their application in regenerative medicine.
- Open Access
- 24 September 2024
- Published by Elsevier in Journal of Agriculture and Food Research
- Vol. 18
Alkaloid-rich extract of jujube seed regenerate the antiproliferative effect of paclitaxel on paclitaxel-resistant MDA-MB-231 breast cancer cell line in 2D and 3D cultures
- 24 September 2024
- Published by Elsevier in Journal of Agriculture and Food Research
- Vol. 18
Open AccessAlkaloid-rich extract of jujube seed regenerate the antiproliferative effect of paclitaxel on paclitaxel-resistant MDA-MB-231 breast cancer cell line in 2D and 3D cultures
- Open Access
- 14 June 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 26, 251-259
The generation of islet-like insulin-producing cells from Wharton's jelly-derived mesenchymal stem cells on the PES/fish gelatin scaffold
- 14 June 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 26, 251-259
Open AccessThe generation of islet-like insulin-producing cells from Wharton's jelly-derived mesenchymal stem cells on the PES/fish gelatin scaffold
- Open Access
- 6 April 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 27, 251-258
Applications of blood plasma derivatives for cutaneous wound healing: A mini-review of clinical studies
- 6 April 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 27, 251-258
Open AccessApplications of blood plasma derivatives for cutaneous wound healing: A mini-review of clinical studies